You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
Express Scripts
Harvard Business School
Colorcon

Last Updated: February 24, 2020

DrugPatentWatch Database Preview

ALBURX Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: ALBURX
Recent Litigation for ALBURX

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
ABRAXIS BIOSCIENCE, LLC v. SUN PHARMA ADVANCED RESEARCH COMPANY, LTD.2019-08-08
Genentech, Inc. v. Pfizer Inc.2019-04-05
Genentech, Inc. v. Immunex Rhode Island Corp.2019-03-29

See all ALBURX litigation

PTAB Litigation
PetitionerDate
2017-11-09
Cipla Ltd.2017-11-09
Actavis LLC2017-04-04

See all ALBURX litigation

Patent Text Search: US Patents for ALBURX

These patents were identified by searching patent claims

Supplementary Protection Certificates for ALBURX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1490056-7 Sweden   Start Trial PRODUCT NAME: ALBIGLUTIDE; REG. NO/DATE: EU/1/13/908/001002 20140321
C300691 Netherlands   Start Trial PRODUCT NAME: ALBUMINE-FUSIE-EIWIT MET GLUCAGONACHTIG-PEPTIDE 1 (GLP-1)-ACTIVITEIT, OMVATTENDE TWEE TANDEMSGEWIJS GEORIENTEERDE AAN ALBUMINE GEFUSEERDE GLP-1-POLYPEPTIDEN, ZOALS GESPECIFICEERD IN DELEN (I) EN (II) VAN CONCLUSIE 1 VAN EP1463751; ZOALS EEN ALBUMINE-FUSIE-EIWIT MET GLUCAGONACHTIG-PEPTIDE 1 (GLP-1)-ACTIVITEIT, OMVATTENDE TWEE TANDEMSGEWIJS GEORIENTEERDE AAN ALBUMINE GEFUSEERDE GLP-1 (7-36(A8G))-POLYPEPTIDEN, ZOALS EEN ALBUMINE-FUSIE-EIWIT MET GLUCAGONACHTIG-PEPTIDE 1 (GLP-1)-ACTIVITEIT, OMVATTENDE TWEE TANDEMSGEWIJS GEORIENTEERDE AAN HUMAAN SERUM ALBUMINE GEFUSEERDE GLP-1)7-36(A8G))-POLYPEPTIDEN, ZOALS EEN ALBUMIDEFUSIE MET GLUCAGONACHTIG-PEPTIDE 1 (GLP-1)-ACTIVITEIT, OMVATTENDE
238 50005-2014 Slovakia   Start Trial PRODUCT NAME: PAKLITAXEL VO FORME NANOCASTIC VIAZANYCH NA ALBUMIN; REGISTRATION NO/DATE: EU/1/07/428/001 - EU/1/07/428/002 20131230
C01463751/01 Switzerland   Start Trial PRODUCT NAME: ALBIGLUTIDUM; REGISTRATION NO/DATE: SWISSMEDIC 63223 29.09.2014
132014902271575 Italy   Start Trial PRODUCT NAME: PACLITAXEL LEGATO ALL'ALBUMINA FORMULATO IN NANOPARTICELLE(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/01/07/428, 20131220
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Express Scripts
Baxter
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.